Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

NCT01569412 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Her2/Neu Positive Advanced Solid Tumors

Interventions

BIOLOGICAL: Ertumaxomab

Sponsor

Krankenhaus Nordwest